论文信息 - A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis – end of study results from the LOWR HDV-3 study - 字舞流文

A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis – end of study results from the LOWR HDV-3 study

C. Yurdaydın | J. Glenn | H. Dahari | Y. Rotman | C. Koh | T. Heller | O. Etzion | T. Han | D. Kapuria | P. Surana | N. Fryzek | V. Takyar | R. Canales | Nancy Fryzek